Increased vitamin D may protect against multiple sclerosis

By Stephen Daniells

- Last updated on GMT

Higher levels of vitamin D in the body may reduce the risk of
developing the neurological disease multiple sclerosis by as much
as 62 per cent, Harvard researchers report.

Looking at 257 US military personnel with the disease and 51 healthy controls, the researchers reported that, for every 50-nmol/L (nanomoles per litre) increase in 25-hydroxyvitamin D the associated risk of MS decreased by 41 per cent for white/non-Hispanics.

Writing in the current issue of the Journal of the American Medical Association​, lead author Kassandra Munger noted that the inverse association with multiple sclerosis risk was particularly strong for high 25-hydroxyvitamin D levels in younger people.

"If the association reported here reflects a true protective effect of vitamin D, increasing the vitamin D levels of adolescents and young adults could result in an important reduction in MS incidence,"​ wrote lead author Kassandra Munger.

"Such an increase could be achieved using vitamin D supplements."

Vitamin D refers to two biologically inactive precursors - D3, also known as cholecalciferol, and D2, also known as ergocalciferol. The former is produced in the skin on exposure to UVB radiation (290 to 320 nm) and can also be consumed from oily fish. The latter is derived from plants and only enters the body via the diet.

Both D3 and D2 precursors are hydroxylated in the liver and kidneys to form 25- hydroxyvitamin D, the non-active 'storage' form, and 1,25-dihydroxyvitamin D, the biologically active form that is tightly controlled by the body.

Some evidence in the literature has indicated a potential protective effect of vitamin D against MS, said Munger, but this has been inconclusive.

According to the authors, multiple sclerosis (MS) is among the most common neurological diseases in young adults, affecting 350,000 individuals in the United States and 2 million worldwide.

The participants in the study were drawn from U.S. military personnel who have serum samples stored in the Department of Defense Serum Repository, and the controls were matched by age, sex, race/ethnicity, and dates of blood collection.

The researchers report that the main protective effects were observed for people of white ethnicity. When the serum vitamin D levels were classified into five groups (quintiles) ranging from lowest (less than 63 nanomoles per litre) to highest (more than 99.1 nanomoles per litre). The associated risk of MS for whites in the highest quintile was 62 per cent lower than those in the lowest quintile.

On the other hand, serum vitamin D levels were not linked to any effect on MS risk for African Americans and Hispanics. These two ethnic groups had lower 25-hydroxyvitamin D levels than whites.

"Although this association was not seen among blacks, their smaller sample size and substantially lower 25-hydroxyvitamin D levels may have reduced the power to detect an association in this group,"​ said the researchers.

The results agree with previous results, said the researchers, which report a protective role for the vitamin. They also said however that while a direct role of vitamin D is indicated, other explanations cannot be discounted.

"Although unlikely, a genetic predisposition to both MS and circulating low 25-hydroxyvitamin D levels could appear as a protective effect of vitamin D on MS in out study.

"Additionally, we cannot exclude the possibility that some other effect of exposure to UV light, rather than vitamin D production, contributes to protection,"​ said the researchers.

Munger and her colleagues called for a prevention trial among first-degree relatives of individuals with MS, said to be at higher risk of developing MS, to further investigate the potentially protective role of the vitamin.

"Meanwhile, use of vitamin D supplements for MS prevention should not be undertaken until efficacy is proven,"​ they concluded.

The study was supported by grants from the National Institute of Neurological Diseases and Stroke and by a pilot grant from the National Multiple Sclerosis Society.

Source: Journal of the American Medical Association​ Volume 296, Pages 2832-2838 "Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis"​ Authors: K.L. Munger, L.I. Levin, B.W. Hollis, N.S. Howard, A. Ascherio

Related news

Show more

Related products

show more

Your Product Innovation Begins Here: Booth 4055

Your Product Innovation Begins Here: Booth 4055

Content provided by Effepharm Ltd | 22-Oct-2024 | Product Brochure

EffePharm will showcase innovative anti-aging solutions, featuring UthPeak™, world’s first self-GRAS approved NMNH, which boosts NAD+ levels by 10X. UthPeak™...

Algal Oil or Fish Oil: Which Should I Choose?

Algal Oil or Fish Oil: Which Should I Choose?

Content provided by GC Rieber VivoMega™ | 04-Oct-2024 | Infographic

Are you fishing for answers when it comes to omega-3s from fish oil vs. algal oil? Do you find yourself asking if EPA or DHA from fish oil is the same...

Gut and mental health struggles affect consumers

Gut and mental health struggles affect consumers

Content provided by Verb Biotics | 23-Sep-2024 | White Paper

Verb Biotics, a biotech company focused on improving health through the gut microbiome, recently completed its second annual consumer survey to assess...

Related suppliers

Follow us

Products

View more

Webinars